We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate [Yahoo! Finance]
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
DiaMedica Therapeutics GAAP EPS of -$0.15 in-line [Seeking Alpha]
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results [Yahoo! Finance]
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results